Pfizer stock (US7170811035): Earnings beat and analyst upgrade offset COVID vaccine headwinds

Pfizer reported first-quarter results that exceeded Wall Street expectations, with earnings per share of $0.75 versus $0.72 anticipated and revenue of $14.45 billion compared to $13.84 billion expected, according to MarketBeat as of May 11, 2026. Revenue growth accelerated 5.4% year over year, signaling resilience across the company's portfolio despite ongoing challenges in its COVID-19 franchise.

Following the earnings announcement, Erste Group Bank analyst H. Engel raised the firm's FY2027 EPS estimate for Pfizer to $2.84 from $2.83, a modest but meaningful signal of improved long-term earnings expectations. The consensus estimate for full-year 2026 earnings stands at $2.98 per share, indicating that the market has priced in stronger performance than Erste Group's revised forecast.

As of: May 11, 2026

By the editorial team – specialized in equity coverage.

Pfizer: core business model

Pfizer is one of the world's largest biopharmaceutical companies, operating across multiple therapeutic areas including oncology, immunology, cardiovascular disease, and vaccines. The company generates revenue through both branded pharmaceutical products and vaccine sales, with a significant historical reliance on COVID-19 vaccines and treatments that have begun to normalize post-pandemic. Pfizer's business model combines internal research and development with strategic acquisitions and partnerships to expand its product portfolio and market reach.

Main revenue and product drivers for Pfizer

The company's revenue streams include established franchises in primary care and specialty care, alongside newer growth drivers in oncology and obesity-related treatments. However, the sharp decline in COVID-19 vaccine sales—which peaked during the pandemic—continues to pressure overall revenue growth and investor sentiment. Pfizer is actively shifting strategic focus toward oncology and obesity drugs, though most new catalysts remain years away from meaningful commercial contribution, according to market analysis as of May 11, 2026.

Patent disputes and legal uncertainty

A Delaware federal court decision dismissed an attempt to block GlaxoSmithKline's patent claims related to Pfizer and BioNTech's Comirnaty vaccine, leaving the broader intellectual property dispute unresolved. While the ruling did not determine whether Comirnaty infringes on GSK's patents, it added another layer of uncertainty to an already declining franchise. The lack of resolution means potential legal risks remain open-ended, keeping investors cautious about Pfizer's near-term outlook and the company's ability to defend its vaccine intellectual property.

Conclusion

Pfizer's first-quarter earnings beat and analyst upgrade provide near-term support for the stock, demonstrating that the company's non-COVID portfolio remains capable of delivering growth. However, the ongoing decline in COVID-19 revenues, combined with unresolved patent disputes and a multi-year timeline for new product catalysts, creates a mixed outlook for investors. The stock's recent weakness reflects this tension between solid operational performance and structural headwinds in the company's largest recent revenue driver.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.